secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016735
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen becomes clinical-stage with Phase 1 starts for SZN-1326 and SZN-043
----------------------------------------------------------------------------

- Initiated Phase 1 trial for SZN-1326 (ulcerative colitis) in May 2022 and for SZN-043 (alcoholic hepatitis) in June 2022.
- Presented preclinical data for SZN-413 (diabetic retinopathy) at ARVO and for other pipeline programs at Digestive Disease Week.
- Q2 2022 financial results reported but specific figures (revenue, EPS, net loss) not included in provided exhibit text.
- Company noted no treatment-related adverse effects in preclinical toxicology studies for both lead candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022016735/0000950170-22-016735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022016735/srzn-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer